Foghorn Therapeutics, Inc. is a U.S.-based pharmaceutical company with a risk rating score of 30.8, classified as high risk. Specializing in ESG-focused discovery and development, it targets genetically determined dependencies within the chromatin regulatory system. Their Gene Traffic Control platform provides insights into system interactions, aiding in the identification and validation of drug targets. With a focus on developing novel medicines like FHD-286 and FHD-609 for hematologic cancers and solid tumors, Foghorn Therapeutics is revolutionizing the pharmaceutical industry.